Composition, pharmaceutical composition, use of a stable topical composition comprising a nanoemulsion and of at least one antileishmanial compound, and method for the treatment of cutaneous leishmaniasis
US-2024016826-A1 · Jan 18, 2024 · US
Method of treating pulmonary disorders with liposomal amikacin formulations
US9119783B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9119783-B2 |
| Application number | US-201213480246-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 24, 2012 |
| Priority date | May 7, 2007 |
| Publication date | Sep 1, 2015 |
| Grant date | Sep 1, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed herein are methods of treating pulmonary disorders comprising administering to the patient an effective dose of a nebulized liposomal amikacin formulation for at least one treatment cycle, wherein: the treatment cycle comprises an administration period of 15 to 75 days, followed by an off period of 15 to 75 days; and the effective dose comprises 100 to 2500 mg of amikacin daily during the administration period.
First claim
Opening claim text (preview).
I claim: 1. A method of treating a Pseudomonas aeruginosa infection in a human patient comprising administering to the patient an effective dose of a nebulized liposomal amikacin formulation for at least one treatment cycle, wherein: the lipid component of the liposomal amikacin formulation comprises dipalmitoylphosphatidylcholine (DPPC) and a sterol, the at least one treatment cycle comprises an administration period of 20 to 35 days, followed by an off period of 15 to 75 days;…
Assignees
Inventors
Classifications
- A61K31/7036Primary
Human Necessities · mapped topic
- A61K9/127Primary
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9119783B2 cover?
- Disclosed herein are methods of treating pulmonary disorders comprising administering to the patient an effective dose of a nebulized liposomal amikacin formulation for at least one treatment cycle, wherein: the treatment cycle comprises an administration period of 15 to 75 days, followed by an off period of 15 to 75 days; and the effective dose comprises 100 to 2500 mg of amikacin daily during…
- Who is the assignee on this patent?
- Gupta Renu, Insmed Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/7036. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Sep 01 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).